SR 11302: Selective AP-1 Transcription Factor Inhibitor for Cancer Research

Executive Summary: SR 11302 is a crystalline compound (C26H32O2, MW 376.54) that selectively inhibits the AP-1 transcription factor without activating retinoic acid or retinoid X receptors, thus reducing typical retinoid-associated side effects (APExBIO). It has demonstrated potent antiproliferative effects in breast cancer (T-47D), lung cancer (Calu-6), and HeLa cell lines, while showing minimal impact on non-targeted cell types such as F9 and HL-60 cells (Liu et al., 2024). In vivo, SR 11302 suppresses AP-1 activation and papilloma formation in AP-1-luciferase transgenic mice, confirming its chemopreventive potential. The compound is DMSO-soluble (>10 mM), stable at -20°C, and is typically used at micromolar concentrations in experimental workflows. SR 11302 represents an advanced tool for precise AP-1 pathway inhibition in oncology and immunology research.

Biological Rationale

The activator protein-1 (AP-1) transcription factor is a heterodimeric complex formed primarily from proteins of the JUN, FOS, ATF, and MAF families. AP-1 regulates gene expression in response to stimuli such as cytokines, growth factors, and stress, and is a key driver of tumorigenesis, inflammation, and cellular proliferation. Overactivation of AP-1 is linked to enhanced tumor promotion, including in colitis-associated colorectal cancer and various epithelial cancers (Liu et al., 2024). Traditional retinoids, while effective in modulating cell differentiation and apoptosis, often cause adverse effects due to their broad receptor activation profiles. A selective AP-1 inhibitor like SR 11302 offers the ability to dissect and modulate AP-1 mediated pathways while minimizing off-target receptor activation, thus enabling higher specificity in cancer research and chemoprevention (see internal review).

Mechanism of Action of SR 11302 (AP-1 transcription factor inhibitor)

SR 11302 (3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid) is a synthetic retinoid analog. Unlike natural or conventional retinoids, SR 11302 does not activate retinoic acid receptors (RARs) or retinoid X receptors (RXRs). Instead, it binds and inhibits the AP-1 transcription factor complex, thus disrupting the transcription of AP-1 target genes involved in cell proliferation, survival, and tumor promotion (APExBIO product page). In vitro, SR 11302 blocks AP-1-driven luciferase reporter activity and downstream gene expression. In vivo, it inhibits chemical carcinogen-induced AP-1 activation, acting as a chemopreventive agent. Mechanistically, SR 11302 may interfere with DNA binding or dimerization of AP-1 subunits, though its precise binding site is still under investigation (further mechanistic discussion).

Evidence & Benchmarks

• SR 11302 specifically inhibits AP-1 transcription activity without activating RARs or RXRs (Liu et al., 2024).
• In vitro, SR 11302 suppresses proliferation of T-47D (breast cancer), Calu-6 (lung cancer), and HeLa cells at micromolar concentrations (typ. ~1 µM), with minimal effect on F9 and HL-60 cells (source).
• In AP-1-luciferase transgenic mice, SR 11302 reduces AP-1 activation and papilloma formation following carcinogen exposure (dose: 34 nmol in acetone) (Liu et al., 2024).
• SR 11302 is DMSO-soluble at >10 mM and remains stable when stored at -20°C for short-term use (APExBIO technical data).
• SR 11302 was used as a TLR4 pathway antagonist in macrophage polarization assays, helping dissect the interaction between AP-1 activity and immune phenotype in colitis-associated colorectal cancer models (Liu et al., 2024).

This article updates and extends the mechanistic and application details found in SR 11302 from APExBIO, emphasizing new in vivo benchmarks and translational relevance.

Applications, Limits & Misconceptions

SR 11302 is widely utilized in oncology research for dissecting AP-1 dependent transcriptional programs. Key applications include:

• Inhibition of tumor promotion and progression in epithelial and inflammation-driven cancers.
• Functional genomics studies on AP-1 regulated gene networks.
• Assays for chemoprevention screening and combinatorial drug development.
• Delineation of AP-1’s role in immune modulation, such as macrophage polarization in the tumor microenvironment (Liu et al., 2024).

Compared to other AP-1 inhibitor reviews, this article clarifies SR 11302’s selectivity and its lack of RAR/RXR activation, which is crucial in minimizing off-target effects in cell-based and animal models.

Common Pitfalls or Misconceptions

• SR 11302 does not activate RARs or RXRs; it cannot substitute for retinoids in differentiation or apoptosis assays reliant on these pathways.
• Limited or negligible antiproliferative effects in F9 embryonal carcinoma and HL-60 myeloid leukemic cells indicate it is not a universal inhibitor for all cancer types.
• High concentrations or prolonged solution storage (>few days, even at -20°C) may result in compound degradation and loss of activity.
• SR 11302 is not a general immunosuppressant and should not be interpreted as such in immune modulation studies.
• Performance in non-mammalian systems is untested and not recommended without validation.

Workflow Integration & Parameters

SR 11302 is offered by APExBIO as a crystalline solid (SKU: A8185). It dissolves readily in DMSO at concentrations exceeding 10 mM. Solubility can be improved by gentle warming or ultrasonic agitation. For cell-based assays, a working concentration of 1 µM is typical, with dilutions prepared fresh before use. In animal models, a dose of 34 nmol in acetone has been used to suppress AP-1 activity in skin papilloma formation assays (product technical data). Storage at -20°C is recommended, and solutions are best used within days to ensure compound stability. SR 11302 can be integrated into AP-1 luciferase reporter assays, proliferation assays, or used as a TLR4 pathway antagonist in immunological studies. For detailed protocols, see SR 11302: Selective AP-1 Inhibitor for Cancer Research & Workflow, which this article extends by providing new in vivo and immunological context.

Conclusion & Outlook

SR 11302 represents a robust, selective, and validated tool for dissecting AP-1 transcriptional regulation in cancer and immune research. Its ability to block AP-1 without activating retinoid receptors allows for higher specificity and reduced off-target effects relative to classical retinoids. This positions SR 11302 (A8185) as a preferred agent for chemoprevention and mechanistic studies in tumorigenesis, especially where AP-1 signaling is implicated. Future studies may further expand its application to combinatorial therapies and advanced immune-oncology research. For purchase and technical documentation, visit the SR 11302 (AP-1 transcription factor inhibitor) product page.